Study #2021-0305
PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate Cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT
Description
The purpose of this study is to determine whether 177Lu-PSMA-617 improves the rPFS or death compared to a change in ARDT in mCRPC participants that were previously treated with an alternate ARDT and not exposed to a taxane-containing regimen in the CRPC or mHSPC settings. Approximately 450 participants will be randomized (225 per treatment group).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Prostatic Neoplasms
Study phase:
Phase III
Physician name:
Christopher Logothetis
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-888-714-4981
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.